A practical reference on Chromatogram: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-01 and is reviewed periodically as new material appears.
Quality control laboratories use HPLC to check identity, purity, concentration, and stability of raw materials and finished products. A validated method specifies the column, mobile phase, flow rate, detection wavelength, injection volume, and run time. Samples are prepared and compared against reference standards of known concentration. The resulting chromatogram provides quantitative data, such as assay values and impurity levels. This approach is common in pharmaceutical, food, environmental, and industrial testing where consistent measurements are required.
Method validation demonstrates that an analytical procedure is suitable for its intended purpose. Typical validation characteristics include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Regulatory guidance from bodies such as the International Council for Harmonisation and the United States Pharmacopeia outlines expectations, though specific criteria depend on the product and method. System suitability tests are run before sample analysis to confirm resolution, peak symmetry, column efficiency, and injection repeatability. Failure of these checks can invalidate a batch of measurements.
Practical HPLC testing depends on careful sample preparation and instrument maintenance. Samples may require filtration, dilution, pH adjustment, or extraction to avoid column damage and matrix interference. Mobile phases are degassed and filtered, and columns are equilibrated before injection. Common problems include peak tailing, baseline drift, ghost peaks, carryover, and co-elution of analytes. Documentation of instrument logs, calibration records, and electronic audit trails supports data integrity and traceability. Ongoing training and routine maintenance help reduce variability between analysts and laboratories.
Separation in HPLC depends on the chemistry of the stationary phase, the composition of the mobile phase, and the physical properties of the column. Reverse-phase separations use a nonpolar stationary phase and a polar mobile phase, and they are common for many organic compounds. Ion-exchange, size-exclusion, and normal-phase modes serve other classes of analytes. Gradient elution changes solvent strength over time, while isocratic elution holds it constant. Flow rate, temperature, particle size, and column length all influence peak shape and resolution. Detection may use ultraviolet absorbance, fluorescence, refractive index, or mass spectrometry, depending on the analyte and the required sensitivity.
Routine HPLC testing compares a sample result with a calibration curve prepared from known reference standards. Peak area or peak height is plotted against concentration, and the curve is used to estimate unknown amounts. Retention time supports tentative identification when compared with a standard, though mass spectrometry or another confirmatory method may be needed for definitive identification. Pre-run checks verify repeatability, resolution, and peak symmetry before sample analysis. Limits of detection and quantification describe the smallest amounts that can be reliably observed or measured. Sample preparation, filtration, and degassing help prevent column damage and inconsistent results.
High-performance liquid chromatography is an analytical technique that separates components in a liquid sample. A pump moves a liquid mobile phase through a column packed with a solid stationary phase. Compounds interact differently with both phases and travel at different rates, leaving the column at distinct retention times. A detector records these arrivals as peaks on a chromatogram. The resulting pattern supports identification and quantification of substances in mixtures. Modern instruments use high pressure to force solvent through small particles, which improves speed and resolution compared with older low-pressure liquid chromatography methods.
| Parameter | Typical acceptance criterion | Notes |
|---|---|---|
| Resolution | ≥ 1.5 | Baseline separation of adjacent peaks |
| Tailing factor | ≤ 2.0 | Peak symmetry measure |
| Theoretical plates | > 2000 | Column efficiency indicator |
| Injection repeatability | ≤ 2% RSD | Relative standard deviation for replicate injections |
| Linearity | r² ≥ 0.995 | Calibration curve over the working range |
Developing an HPLC method begins with defining the purpose, such as quantifying a main component, measuring impurities, or confirming identity. Analysts select separation mode, column, mobile phase, detection, and sample preparation based on analyte properties and matrix. Experiments vary solvent strength, pH, buffer type, and temperature to achieve resolution between critical peaks. The goal is a robust method that produces reliable results across instruments and operators. Method development often involves trial runs and statistical optimization.
Validation demonstrates that a method is suitable for its intended use. Typical performance characteristics include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Regulators and standards organizations provide frameworks, but specific requirements depend on the application and jurisdiction. System suitability tests are run before sample analysis to confirm resolution, peak symmetry, retention time repeatability, and sensitivity. A validated method is not permanently fixed; changes may require partial or full revalidation.
Routine HPLC testing depends on controlled reagents, calibrated instruments, and documented procedures. Columns degrade over time, so retention times and peak shapes are monitored for drift. Mobile phases are filtered and degassed to prevent pump damage and detector noise. Reference standards must be traceable and stored under suitable conditions. Data handling systems record injections, calculations, and audit trails. Quality control samples interspersed with unknowns help detect errors during a run.
Instrumentation includes a solvent delivery system, an autosampler, a column oven, and one or more detectors. Reversed-phase columns with chemically modified silica are widely used, but normal-phase, ion-exchange, size-exclusion, and affinity modes exist for specific separations. Detectors may rely on ultraviolet absorbance, fluorescence, refractive index, or mass spectrometry. Column temperature, mobile phase composition, and flow rate are adjusted to improve resolution. System pressure is monitored because rising pressure can indicate column blockage or deteriorating packing.
Separation performance depends on particle size, pore size, column length, and the chemistry of the stationary phase. Smaller particles generally improve efficiency but require higher pressure and suitable instrumentation. The mobile phase often contains buffers and organic solvents that influence retention and selectivity. Testing labs select conditions based on the analytes, sample matrix, and required sensitivity. Method development frequently involves screening several columns and solvent mixtures before a final set of conditions is chosen.
High-performance liquid chromatography is an analytical technique that separates components in a liquid sample by passing them through a packed column under pressure. A pump delivers a mobile phase at a controlled flow rate, and an injector introduces the sample into the stream. Differences in how analytes partition between the mobile phase and the stationary phase cause them to exit the column at different times. Detection then records a signal proportional to the amount of each separated substance. The resulting chromatogram provides retention times and peak areas for identification and quantification.
== T == T7 RNA polymerase - taq polymerase - TATA box - taurochenodeoxycholate 6α-hydroxylase - taxadiene 5alpha-hydroxylase - taxane 10beta-hydroxylase - TAZ zinc finger - Tbf5 protein domain - technology transfer - template - termination codon - terminator - tertiary structure - tet resistance - TGF beta Activation - thymine - tissue-specific expression - tm - trans - trans-feruloyl-CoA hydratase - transcript - transcription - transcription factor - transcription/translation reaction - transcriptional start site - transfection - transformation (genetics) - transformation (with respect to bacteria) - transfection (with respect to cultured cells) - transgene - transgenic - transient transfection - transition - translation - transposition - transposon - transversion - triplet - trisomy - tRNA - tRNA (adenine-N1-)-methyltransferase - tRNA (guanine-N1-)-methyltransferase - tRNA-dihydrouridine synthase - TUG-UBL1 protein domain - tumor suppressor - tumor suppressor gene -
==== Los Angeles ==== In Los Angeles, hundreds of Mexican women were sterilized after giving birth at Los Angeles County Hospital. In the documentary No Mas Bebes, some of the women who were sterilized at this hospital shared their experiences. All of the women shown did not want to be sterilized. "In California, at least into the 1950s, compulsory sterilization was consistently described as a public health strategy that could breed out undesirable defects from the populace and fortify the state as a whole". Women who were unhappy with this situation marched and protested to speak up for their reproductive rights.
Gepirone, sold under the brand name Exxua, is a medication used for the treatment of major depressive disorder. It is taken orally. Side effects of gepirone include dizziness, nausea, insomnia, abdominal pain, and dyspepsia (indigestion). Gepirone acts as a partial agonist of the serotonin 5-HT1A receptor. An active metabolite of gepirone, 1-(2-pyrimidinyl)piperazine, is an α2-adrenergic receptor antagonist. Gepirone is a member of the azapirone group of compounds. Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. It was approved for the treatment of major depressive disorder in the United States in September 2023. This came after the drug had been rejected by the Food and Drug Administration (FDA) three times over two decades due to insufficient evidence of effectiveness.
=== Provincial funding === Shortly after the first human trials on PTX-COVID19-B began in late January, on February 11, 2021, Manitoba Premier Brian Pallister announced a "term sheet" between the province and Providence Therapeutics through which Manitoba would receive 2 million doses of PTX-COVID19-B pending its approval by Health Canada. The term sheet includes "best-price guarantee" PTX-COVID19-B. According to a provincial statement released by the Manitoba government, pending approval of the vaccine, the actual manufacturing would take place in Winnipeg by Emergent BioSolutions. Pallister said that, "Building a secure, made-in-Canada vaccine supply will put Canadians at the head of the line to get a COVID vaccine, where we belong." The down payment would be 20% with a subsequent 40% to be paid when the vaccine was approved by Health Canada; the balance would be paid on delivery of the doses. Specifics about the contract were released in April 2021: the total cost was estimated as CAD$36 million and the agreement included a clause for a non-refundable advance payment of CAD$7.2 million. Sorenson made this comment to Global News: "Under no circumstances is Manitoba going to be on the hook for $7.2 million unless they get real value out of it".
Sources: en.wikipedia.org
== Endurance sports == The use of performance-enhancing drugs in sport has become an increasing problem across a wide range of sports. It is defined as any substance or drug that, when taken, gives an athlete an unfair advantage relative to a "clean" athlete. The banning of these drugs promotes a level playing field and equality among athletes. The use of 'the suit' in swimming, which gives athletes an advantage in the way of hydrodynamics, has been banned from international competition due to the unfair advantage it delivered. The drugs taken by athletes differ widely based on the performance needs of the sport. Erythropoietin (EPO) is largely taken by endurance athletes who seek a higher level of red blood cells, which leads to more oxygenated blood, and a higher VO2 max. An athlete's VO2 max is highly correlated with success within endurance sports such as swimming, long-distance running, cycling, rowing, and cross-country skiing. EPO has recently become prevalent amongst endurance athletes due to its potency and low degree of detectability when compared to other methods of doping such as blood transfusion. While EPO is believed to have been widely used by athletes in the 1990s, there was not a way to directly test for the drug until 2002 as there was no specific screening process to test athletes. Athletes at the Olympic Games are tested for EPO through blood and urine tests. Stringent guidelines and regulations can lessen the danger of doping that has existed within some endurance sports. A notable case being TJ Dillashaw.
In November 2020, "AJISWEET RA", produced in Japan cooperating with Morita Kagaku Kogyo Co., Ltd., was newly launched to the US as stevia sweetener reducing bitterness and off-flavors. In December, Ajinomoto Group made a wholly owned supplement company in Ireland by a share purchase agreement with Nualtra Limited in order to enter Europe's oral nutritional supplements market. In December 2020, Ajinomoto was included by CDP in its "Climate Change A List for 2020" for the first time, as one of the most outstanding companies in terms of climate change-related initiatives and information disclosure for its climate impact. in 2021, Ajinomoto joined WIPO GREEN as an official partner in an effort to address climate change. In February 2021, Ajinomoto Animal Nutrition Group Inc. transferred all of its 100% equity stake in Ajinomoto Animal Nutrition Europe S.A., a European feed-use amino acid company, to METabolic EXplorer, a French operating company with strengths in R&D of fermentation technologies. On the Tokyo Nutrition Summit 2021, held on December 7–8, 2021, Ajinomoto announced its Nutrition Commitment, a specific goal for improving nutrition, and registered it on the commitment registration website (Global Nutrition Report) on October 26. Ajinomoto Co., Inc. has planned and resolved the MediumTerm ASV Management 2030 Roadmap at its Board of Directors Meeting of February 28, 2023.
His regiment was paraded on the dock, as Queen Victoria was to inspect them before they left. Up and down the ranks the Queen progressed, stiff as a ramrod until she came opposite the young Lord Morley. Turning to an aide, she rested her hand on his shoulder and dabbed tears from her eyes. 'My fine young men all going to war', the Queen murmured, 'so few of them will ever come back'. Lord Morley told me that he did not find the Queen's words reassuring as he boarded the liner that was to take him and his regiment to South Africa.
Sources: en.wikipedia.org
Method validation is the documented process of confirming that an HPLC procedure is suitable for its intended use. It evaluates accuracy, precision, specificity, linearity, range, detection limits, and robustness. Validation criteria depend on the regulatory context and the sample type.
System suitability tests are short checks performed before or during an HPLC run to verify instrument and method performance. They often include resolution, tailing factor, theoretical plates, and injection precision. Results must meet predefined limits for sample data to be accepted.
HPLC retention time alone cannot definitively identify an unknown substance. A match with a reference standard under identical conditions provides supporting evidence. Confirmation typically requires mass spectrometry, nuclear magnetic resonance, or another orthogonal technique.
HPLC testing measures the presence and amount of one or more compounds in a liquid sample. It separates mixture components and records detector responses as peaks, which are compared with reference standards. Results are usually reported as concentrations or relative percentages.